实体恶性肿瘤住院患者中肝素诱导性血小板减少症的发生率与结局:基于美国全国住院患者样本数据库的分析
本研究利用美国全国住院患者样本数据库(NIS)2012年1月至2015年9月的数据,分析实体恶性肿瘤相关住院中肝素诱导性血小板减少症(HIT)的发生率、发病率、死亡率和经济负担。实体恶性肿瘤中的HIT虽罕见,但与发病率和死亡率增加相关。
核心结论
- 实体恶性肿瘤中的HIT虽罕见,但与血栓事件、死亡率和医疗资源使用增加相关。
研究设计与样本
- 基于美国全国住院患者样本数据库(NIS)2012年1月至2015年9月的回顾性分析。
- 研究人群为具有实体恶性肿瘤相关诊断的住院患者,共7 437 049例住院。
关键数值与推荐
- HIT定义为肝素类产品相关的免疫介导不良反应,表现为血小板减少伴或不伴血栓形成。
- 主要结局为HIT发生率;次要结局包括静脉血栓、动脉血栓、死亡率、住院时长、总住院费用和出院去向。
临床怎么用
- 实体恶性肿瘤住院患者应警惕HIT可能,尤其出现血小板减少或血栓事件时。
- HIT与血栓事件和死亡风险增加相关,需及时识别并管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse reaction to heparin products characterized by thrombocytopenia with or without thrombosis. This study aimed to determine the incidence, morbidity, mortality and economic burden of HIT in solid-malignancy-related hospitalizations. We analyzed the National Inpatient Sample Database (NIS), the largest public database of hospital admissions in the United States, from January 2012 to September 2015. The primary outcome of the study was the incidence of HIT. Secondary outcomes included incidence of venous thrombosis (acute deep venous thrombosis and pulmonary embolism), arterial thrombosis (thrombotic stroke, myocardial infarctions and other arterial thromboembolism), mortality associated with HIT, length of stay, total hospital charges and disposition. During the study period, 7 437 049 hospitalizations had an associated diagnosis of solid malignancy. Approximately 0·08% (n = 6225) hospitalizations had a secondary diagnosis of HIT in this population. The standardized incidence of total thrombotic events was higher in the solid malignancy with HIT compared to the solid malignancy without HIT group (24·7% vs. 6·8%, P < 0·001). The standardized mortality rate was 4·8% in solid malignancy with HIT compared to 3·4% in the without HIT group (OR, 1·53; 95% CI, 1·25-1·89; P < 0·001). HIT in solid malignancy is a rare condition but associated with increased morbidity and mortality.
引用
- Kumar R, Bhandari S, Singh SRK, et al. Incidence and outcomes of heparin-induced thrombocytopenia in solid malignancy: an analysis of the National Inpatient Sample Database. Br J Haematol. 2020. PMID: 31990984. doi:10.1111/bjh.16400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。